Effect of gene mutation combined with clinical complication index on prognosis of myelodysplastic syndrome
ZHOU Ming
HU Meng-meng
SHEN Ying-ying
ZHENG Zhi-yin
WU Li-qiang
YU Qing-hong
WANG Bo
YE Bao-dong
SHEN Jian-ping
LIN Sheng-yun
Abstract：Objective To investigate the impact of gene mutation and age-adjusted Chilson Comorbidity Index(aCCI)on the prognosis of patients with myelodysplastic syndrome(MDS).Methods Data of 155 patients with myelodysplastic syndrome(MDS)who underwent treatment in the First Affiliated Hospital of Zhejiang Chinese Medical University and other partner hospitals from March 2019 to October 2023 were selected.Cox proportional regression risk models were utilized to screen the risk factors influencing the prognosis of MDS patients.Results The IPSS-R risk stratification(HR 1.337,95％CI 1.055-1.694),aCCI(HR 1.317,95％CI 1.164-1.490),mutation genes TP53(HR 3.532,95％CI 2.034-6.135),NRAS(HR 3.278,95％CI 1.528-7.031)and ZRSR2(HR 4.163,95％CI 1.625-10.665)all exerted negative impacts on the overall survival(OS)of MDS patients(P＜0.05).Meanwhile,aCCI(HR 1.393,95％CI 1.114-1.743),the mutated gene RUNX1(HR 2.259,95％CI 1.043-4.890)and KRAS(HR 4.398,95％CI 1.471-13.148)adversely affected the leukemia-free survival(LFS)in MDS patients(P＜0.05).Conclusion Gene mutation and aCCI influence the prognosis of MDS patients,and there might be a recessive connection between these two risk factors.
Keywords：myelodysplastic syndromegene mutationcharlson comorbidity indexageprognosis
Publication Date：2025-01-31
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 67-72 )